These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 16167015

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Pathogenesis and pathology of graft-vs.-host disease.
    Wagner JE, Vogelsang GB, Beschorner WE.
    Am J Pediatr Hematol Oncol; 1989; 11(2):196-212. PubMed ID: 2665549
    [Abstract] [Full Text] [Related]

  • 43. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation by removal of T-cells].
    de Gast GC, Verdonck LF, van Kempen-Harteveld ML, Gerritsen H, Dekker AW.
    Ned Tijdschr Geneeskd; 1986 May 10; 130(19):868-71. PubMed ID: 3520348
    [No Abstract] [Full Text] [Related]

  • 44. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM, Gorechlad J, Larsen CP, Waller EK.
    Biol Blood Marrow Transplant; 2006 Dec 10; 12(12):1239-49. PubMed ID: 17162205
    [Abstract] [Full Text] [Related]

  • 45. Advances in the understanding of acute graft-versus-host disease.
    Morris ES, Hill GR.
    Br J Haematol; 2007 Apr 10; 137(1):3-19. PubMed ID: 17359368
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2006 Apr 10; 12(4):397-407. PubMed ID: 16545723
    [Abstract] [Full Text] [Related]

  • 49. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
    Pachnio A, Dietrich S, Klapper W, Humpe A, Schwake M, Sedlacek R, Gramatzki M, Beck C.
    Bone Marrow Transplant; 2006 Jul 10; 38(2):157-67. PubMed ID: 16820783
    [Abstract] [Full Text] [Related]

  • 50. Management of acute graft-versus-host disease.
    Bacigalupo A.
    Br J Haematol; 2007 Apr 10; 137(2):87-98. PubMed ID: 17391488
    [Abstract] [Full Text] [Related]

  • 51. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I.
    Biol Blood Marrow Transplant; 2006 Oct 10; 12(10):1073-84. PubMed ID: 17084371
    [Abstract] [Full Text] [Related]

  • 52. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S.
    Blood Cells Mol Dis; 2008 Oct 10; 40(1):48-54. PubMed ID: 17827036
    [Abstract] [Full Text] [Related]

  • 53. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Avanzini MA, Maccario R, Locatelli F, Giebel S, Santos CD, Bernardo ME, Pagliara D, Montagna D, Longo S, Amendola G, Marconi M.
    Exp Hematol; 2006 Oct 10; 34(10):1429-34. PubMed ID: 16982336
    [Abstract] [Full Text] [Related]

  • 54. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N, Chamakhi I, Perreault C, Roy DC, Sauvageau G, Ducruet T, Busque L, Fish D, Bélanger R, Roy J.
    Exp Hematol; 2006 Jan 10; 34(1):107-14. PubMed ID: 16413397
    [Abstract] [Full Text] [Related]

  • 55. CTL clones isolated from an HLA-Cw-mismatched bone marrow transplant recipient with acute graft-versus-host disease.
    Sugimoto K, Murata M, Terakura S, Naoe T.
    J Immunol; 2009 Nov 01; 183(9):5991-8. PubMed ID: 19812210
    [Abstract] [Full Text] [Related]

  • 56. Allogeneic hematopoietic transplantation and leukemia: a second chance for T cells?
    Kuppen PJ.
    Transplantation; 2008 Jan 15; 85(1):7-8. PubMed ID: 18192904
    [No Abstract] [Full Text] [Related]

  • 57. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
    Liu YP, Li Z, Nador RG, Strober S.
    Transplantation; 2008 Feb 27; 85(4):607-14. PubMed ID: 18347541
    [Abstract] [Full Text] [Related]

  • 58. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA, Carter SL, Freifeld AG, High KP, Godder KT, Papanicolaou GA, Mendizabal AM, Wagner JE, Yanovich S, Kernan NA.
    Biol Blood Marrow Transplant; 2007 Dec 27; 13(12):1487-98. PubMed ID: 18022579
    [Abstract] [Full Text] [Related]

  • 59. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z.
    Eur J Haematol; 2008 Sep 27; 81(3):226-35. PubMed ID: 18573173
    [Abstract] [Full Text] [Related]

  • 60. Cellular infiltrates in the target organs associated with acute graft-versus-host disease.
    Renkonen R, Häyry P.
    Bone Marrow Transplant; 1987 Dec 27; 2(4):333-46. PubMed ID: 3332181
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.